2020 Year in Review - Ovarian Cancer
2020 Year in Review - Ovarian Cancer | January 20, 2021
Although researchers noted a trend toward increased incidence of secondary hematologic malignancy in patients with newly diagnosed ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors, the difference was not statistically significant.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Combination treatment is even more effective in women with ovarian cancer with BRCA mutations or homologous recombination deficiency (HRD)-positive tumors.
2020 Year in Review - Ovarian Cancer | January 20, 2021
In patients with newly diagnosed, advanced ovarian cancer and BRCA mutation, olaparib demonstrated a consistently high reduction in the risk for cancer progression and death.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Robotic interval debulking surgery is efficient and safe when treating patients with advanced ovarian cancer who are receiving neoadjuvant chemotherapy.
2020 Year in Review - Ovarian Cancer | January 20, 2021
NOVA clinical trial data outcomes were superior to the real-world outcomes for niraparib, highlighting the critical need for better understanding of variables impacting poly (ADP-ribose) polymerase (PARP) inhibitor outcomes in clinical practice.
2020 Year in Review - Ovarian Cancer | January 20, 2021
The RESPONSE study will help characterize patient characteristics and regional specific therapeutic management strategies adopted in 7 countries to better understand poly (ADP-ribose) polymerase (PARP) inhibitor use and its impact on outcomes.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Researchers evaluated the connections between safety and efficacy and rucaparib pharmacokinetic exposure in patients with recurrent ovarian cancer.
2020 Year in Review - Ovarian Cancer | January 20, 2021
Treatment with niraparib improves progression-free survival (PFS) in patients with ovarian cancer regardless of their biomarker status.
2020 Year in Review - Ovarian Cancer | January 20, 2021
An analysis of phase 3 data from ARIEL3 was reviewed, providing insight into treatment-emergent adverse events (AEs) in patients receiving maintenance therapy with rucaparib for ovarian cancer.
2020 Year in Review - Ovarian Cancer | January 20, 2021
An investigation of whether adding a maintenance therapy regimen of olaparib combined with bevacizumab provided a benefit beyond first progression in patients with newly diagnosed advanced high‐grade ovarian carcinoma.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512